1
Home
Companies

Chinook Therapeutics

#3528

Rank

$2.62B

Marketcap

US United States

Country

Chinook Therapeutics
Leadership team

Mr. Eric L. Dobmeier J.D. (Pres, CEO & Director)

Mr. Tom Frohlich (Chief Operating Officer)

Mr. Andrew James King D.V.M., Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology
Number of Employees
100 - 500
Headquarters
Vancouver, Alberta, Canada
Established
2019
Company Registration
SEC CIK number: 0001435049
Revenue
20M - 100M
Traded as
KDNY
URL
https://www.chinooktx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
History

Chinook Therapeutics was founded in March 2015 by a team of highly experienced executives and investors from the pharmaceutical, biotechnology and venture capital industries. We have established a collaboration with Northwell Health to co-develop best-in-class biotherapeutics for patients with serious immune-mediated respiratory diseases. Our team consists of seasoned professionals with a proven track record of drug development success and deep expertise in drug discovery, biotherapeutics, clinical development, and regulatory affairs.

Mission
Our mission is to develop innovative biologics that have the potential to address serious unmet medical needs and improve patients’ lives.
Vision
Our vision is to be a leading developer of specialized biotherapeutics that are capable of delivering meaningful therapeutic solutions to treat serious diseases such as respiratory conditions, autoimmune diseases and cancer.
Key Team

Mr. Eric H. Bjerkholt M.B.A. (Chief Financial Officer)

Ms. Noopur Batsha Liffick (VP of Investor Relations & Corp. Communications)

Mr. Kirk D. Schumacher J.D. (Sr. VP & Gen. Counsel)

Ms. Jodi Jamieson (VP of HR)

Dr. Alan Glicklich M.D. (Exec. Officer)

Ms. Delphine Imbert Ph.D. (Sr. VP of CMC & Technical Operations)

Dr. Charlotte Jones-Burton M.D., M.S. (Sr. VP of Product Devel. & Strategy)

Recognition and Awards
Chinook Therapeutics has been recognized with multiple awards and distinctions, including being named a Fierce 15 Company of 2016, an Oregon Technology Awards Finalist for Technology Innovation of the Year in 2017, and a Top 25 Biotech of 2017 by Fiercebiotech.
References

https://in.investing.com/equities/aduro-biotech-inc

https://finance.yahoo.com/quote/KDNY/profile?p=KDNY

https://www.crunchbase.com/organization/chinook-therapeutics

https://sec.report/CIK/0001435049

https://companiesmarketcap.com/

https://www.chinooktx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Chinook Therapeutics
Leadership team

Mr. Eric L. Dobmeier J.D. (Pres, CEO & Director)

Mr. Tom Frohlich (Chief Operating Officer)

Mr. Andrew James King D.V.M., Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology
Number of Employees
100 - 500
Headquarters
Vancouver, Alberta, Canada
Established
2019
Company Registration
SEC CIK number: 0001435049
Revenue
20M - 100M
Traded as
KDNY
URL
https://www.chinooktx.com